Recruiting

Testing a new medicine for sickle cell disease complications

Plain-English translation of NCT07187973 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

Read our Sickle Cell Disease research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage clinical trial testing a new medication called in adults with sickle cell disease. The study will examine whether the medication is safe and how the body processes it. Researchers will gradually increase the dose over time to find the right amount that works best.

Sickle cell disease causes serious complications like painful crises, organ damage, and vision problems. Current treatments help, but researchers are looking for new options to better manage these complications and improve patients' quality of life.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with sickle cell disease (HbSS or HbSC type)
you have experienced sickle cell-related complications in the past year, such as pain crises, eye problems, stroke, bone damage, hearing loss, or organ complications
your hemoglobin level is at least 7.0 g/dL (or 9.0 g/dL if you are one of the first two participants)
your blood work shows specific markers of active sickle cell disease, including higher-than-normal reticulocyte counts and adequate iron levels

You likely don't qualify if…

you are pregnant or breastfeeding, or unwilling to use effective birth control during and for 4 months after the study
you have had a vasectomy (if male) or lack appropriate birth control options (if female of childbearing age)
you have had recent changes to your current sickle cell medications (such as hydroxyurea, L-glutamine, or crizanlizumab) within the past 2 months
your ferritin level (iron storage marker) is extremely high (above 1,000 ng/mL) or below required thresholds

What participation looks like

You will take the medication by mouth at three gradually increasing dose levels over the course of the study. You'll attend multiple clinic visits where researchers will monitor your safety through blood tests, physical exams, and check-ins about how you're feeling. The study will track how your body responds to the medication and watch for any side effects.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(6 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Emory University, Atlanta, Georgia

Augusta University, Augusta, Georgia

Innovative Hematology - Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana

Mount Sinai Hospital, New York, New York